Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death. Treatment with analog rather than ...
The May 29, 2026 PDUFA targets pediatric approval of Afrezza for type 1 or type 2 diabetes, leveraging INHALE-1 outcomes versus rapid-acting analogs plus basal insulin. INHALE-1 was open-label and ...
Children and adolescents with diabetes using inhaled insulin had an increase in HbA1c from baseline to 1 year, according to data from the INHALE-1 extension trial published in Diabetes Technology & ...
(HealthDay News) — For patients with type 2 diabetes, the risk of acute myocardial infarction (AMI) is not significantly different for long-acting insulin analogs versus other basal insulin therapies, ...
Insulin therapy is central to type 1 diabetes and many cases of type 2. It lowers glucose effectively, yet it also introduces predictable risks. Understanding side effects helps patients plan […] ...
ORLANDO -- For type 1 diabetes patients, switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) maintained glycemic control -- for those who used it as intended, the ...
SAN DIEGO -- Investigational once-weekly insulin icodec outperformed once-daily insulin glargine U100 when it came to glycemic control in type 2 diabetes, the phase IIIa ONWARDS 1 trial found. Over ...
Insulin remains one of the most important treatments for people living with diabetes. Whether someone has Type 1 diabetes or advanced Type 2 diabetes, insulin therapy helps control blood sugar levels, ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved insulin glargine-aglr, a second biosimilar to Sanofi’s insulin glargine, to improve glycemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results